903129-78-2

Usage

Uses

Used in Medicinal Chemistry:
6-Bromo-imidazo[1,2-a]pyridine-8-carboxylic acid serves as a valuable building block in the synthesis of biologically active molecules. Its unique structure allows for the development of compounds with antiviral and antibacterial properties, making it a key component in creating new pharmaceutical agents.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, 6-Bromo-imidazo[1,2-a]pyridine-8-carboxylic acid is utilized for its potential to contribute to the creation of novel drugs. Its incorporation into drug candidates can lead to the discovery of treatments for a variety of diseases and conditions, highlighting its importance in advancing medical therapies.
Used in Antiviral and Antibacterial Agents:
6-Bromo-imidazo[1,2-a]pyridine-8-carboxylic acid is applied as a key component in the development of antiviral and antibacterial agents due to its ability to be modified and incorporated into molecules with potent bioactivity against infectious pathogens.
Used in Drug Discovery:
6-Bromo-imidazo[1,2-a]pyridine-8-carboxylic acid is used as a starting material in drug discovery processes, where its chemical properties can be exploited to design and synthesize new therapeutic agents with improved efficacy and selectivity for targeted diseases.

Upstream product

• 97-97-2 chloroacetaldehyde dimethyl acetal 
• 52833-94-0 2-amino-5-bromonicotinicacid 
• 107-20-0 2-chloroethanal 

Relevant academic research and scientific papers

Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-molecule inhibitors is an emerging immunotherapeutic approach. A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction. Among them, compound A22 exhibited the most potent activity, as assessed by homogenous time-resolved fluorescence assay, with an IC50 of 92.3 nM. Furthermore, A22 dose-dependent elevated interferon-γproduction in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. We concluded that A22 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. In addition, we explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogues of the Bristol-Myers Squibb chemical series. These studies pave the way for future drug design.

IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF

The invention provides compounds of formula (1), stereoisomers and tautomers thereof, or pharmaceutically acceptable salts, solvates and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by one or more proinflammatory cytokines selected from TNF-a, IL-Ιβ, IL-6, IL-8, IL-12, IL-17 or IL-23.

IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.